Octagam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Octagam, is an immunoglobulin presented as a solution for intravenous use. It replaces missing antibodies and is used to treat immune deficiencies and certain autoimmune conditions in both children and adults.

GNH USA supplies Octagam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Octagam is an immunoglobulin therapy that acts on disorders of the immune system. It is indicated for: - Primary immunodeficiency diseases: provides replacement antibodies to reduce infection frequency. - Chronic inflammatory demyelinating polyneuropathy (CIDP): helps improve muscle strength and functional ability. - Idiopathic thrombocytopenic purpura (ITP): raises platelet counts and reduces bleeding risk.

Adverse reactions to Octagam vary with frequency and severity.

Common Side Effects: - Headache - Fever or chills - Nausea - Fatigue - Mild hypertension - Injection site erythema

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Acute renal failure - Thromboembolic events - Aseptic meningitis - Hemolytic anemia - Severe hypotension

Before using Octagam, consider the following precautions: - Renal function: assess baseline kidney status, especially in patients with pre‑existing impairment. - Cardiovascular health: monitor blood pressure and fluid status during infusion. - Thrombotic risk: evaluate history of clotting disorders before therapy. - Immunoglobulin A deficiency: test for anti‑IgA antibodies to avoid severe reactions. - Concomitant immunosuppressants: watch for heightened infection risk. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other medicines; monitoring is advised.

Major Interactions (Avoid): - Live vaccines: concurrent use can diminish vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect, requiring INR monitoring. - Diuretics: can increase risk of renal stress during infusion. - Corticosteroids: may mask early signs of infection. - ACE inhibitors: potential for additive blood‑pressure effects. - Other immunoglobulin products: avoid overlapping therapy to prevent overload.